Fritschka E, Kribben A, Hoyer J, Rothschild M, Thiede H M, Distler A, Philipp T
Department of Medicine, Klinikum Steglitz, Freie Universität Berlin, Federal Republic of Germany.
J Hypertens Suppl. 1987 Dec;5(5):S349-52.
We examined normotensive and hypertensive subjects in order to determine whether changes in platelet alpha 2-adrenoceptor density following alterations in plasma noradrenaline are related to changes in noradrenaline (NA) reactivity. Noradrenaline reactivity, plasma NA, alpha 2-adrenoceptor density, and adenylate cyclase activity were measured before and after a 24-h infusion of NA at a subpressor dose (0.02 micrograms/kg per min, n = 13), and also after application of drugs known to increase (nifedipine and furosemide) or decrease (clonidine) plasma NA. Measurements were obtained 60 min after nifedipine (20 mg in a single dose, n = 13), after 3 weeks on furosemide (30 mg twice a day, n = 8) and after 1 week on clonidine (150 micrograms three times a day, n = 5). Infusion of NA decreased alpha 2-adrenoceptor density (P less than 0.01) and NA reactivity (P less than 0.05). Nifedipine decreased alpha 2-adrenoceptor density and NA reactivity (P less than 0.01 for both) in patients with essential hypertension. The alterations in alpha 2-adrenoceptor densities were paralleled by a decreased adrenaline-induced inhibition of adenylate cyclase activity (P less than 0.01). Furosemide decreased alpha 2-adrenoceptor density (P less than 0.01), the fraction of high-affinity binding sites (P less than 0.01) and NA reactivity (P less than 0.05) in normotensive subjects. Following clonidine all three parameters, alpha 2-adrenoceptor density, the fraction of high affinity sites and NA reactivity, increased (P less than 0.05 for each).(ABSTRACT TRUNCATED AT 250 WORDS)
我们对血压正常和高血压受试者进行了检查,以确定血浆去甲肾上腺素改变后血小板α2-肾上腺素能受体密度的变化是否与去甲肾上腺素(NA)反应性的变化有关。在以亚升压剂量(0.02微克/千克每分钟,n = 13)静脉输注NA 24小时之前和之后,以及在应用已知可增加(硝苯地平和呋塞米)或降低(可乐定)血浆NA的药物之后,测量NA反应性、血浆NA、α2-肾上腺素能受体密度和腺苷酸环化酶活性。在单次服用硝苯地平(20毫克,n = 13)60分钟后、服用呋塞米3周(30毫克,每日两次,n = 8)后以及服用可乐定1周(150微克,每日三次,n = 5)后进行测量。输注NA降低了α2-肾上腺素能受体密度(P < 0.01)和NA反应性(P < 0.05)。硝苯地平降低了原发性高血压患者的α2-肾上腺素能受体密度和NA反应性(两者均P < 0.01)。α2-肾上腺素能受体密度的改变与肾上腺素诱导的腺苷酸环化酶活性抑制作用降低平行(P < 0.01)。呋塞米降低了血压正常受试者的α2-肾上腺素能受体密度(P < 0.01)、高亲和力结合位点比例(P < 0.01)和NA反应性(P < 0.05)。服用可乐定后,α2-肾上腺素能受体密度、高亲和力位点比例和NA反应性这三个参数均增加(各P < 0.05)。(摘要截选至250字)